NASDAQ · RVMD

Revolution Medicines, Inc.

Healthcare · Biotechnology

$196.94▲ 0.52% ($1.02)at close

Pre-market$196.92▼ 0.01%7:37 AM ET

52-week

$42.18$224.31

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -37.23%/yr over the past 2 years.

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$196.94

Estimated value / share

Unavailable

Base scenario

USD

Need current revenue and shares outstanding to build the revenue-driven FCFF model.

Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.

Year 1 growth — · Ending margin — · Discount rate 12.7%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 18, 2026, 11:39 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 349.53%FCF (TTM): -126.72%

What changed

The stock rose 349.53% over the last year. Free cash flow declined 126.72% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers.

CEOMark A. Goldsmith

SectorHealthcare

IndustryBiotechnology

Employees883

IPO dateFeb 13, 2020

https://www.revmed.com

Market multiples

Forward P/E—

EV/EBITDA-13.68

Enterprise value$14.92B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-79.09%▼21.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$247.00▲25.42%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est -$2.41 · Revenue est $19.44M

View